While current clinical practice for glioma diagnosis and prognosis primarily relies on molecular and methylation classification, which provides critical insights into tumor grade, IDH mutation status, and MGMT promoter methylation [71, 72], the addition of CDCA gene expression as a biomarker could offer complementary information. This evidence concerns the gene MGMT and neoplasm.